Dihydropyrrolopyridine inhibitors of ROR-gamma
Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by RORγ. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.
1. A compound of the formula:
or a pharmaceutically acceptable salt thereof.
2. A pharmaceutical composition comprising a compound of the formula:
or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
3. A method of treating a disease or disorder selected from psoriasis, psoriatic arthritis (PsA), inflammatory bowel disease (IBD), rheumatoid arthritis, juvenile rheumatoid arthritis, systemic lupus erythematosus (SLE), multiple sclerosis, ankylosing spondylitis, and asthma in a subject, comprising administering to the subject a therapeutically effective amount of a compound having the formula:
or a pharmaceutically acceptable salt thereof.
4. The method of claim 3 , wherein the disease or disorder is psoriatic arthritis (PsA).
5. The method of claim 3 , wherein the disease or disorder is ankylosing spondylitis.
6. The method of claim 3 , wherein the disease or disorder is psoriasis.